Bioventus (BVS) Restructuring Costs (2020 - 2026)

Bioventus (BVS) has reported Restructuring Costs for 6 consecutive years, with -$415000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Restructuring Costs changed N/A year-over-year to -$415000.0; the trailing twelve-month figure through Jun 2026 stood at $39000.0 (up 175.0% YoY), and the FY2025 full-year result was $2.2 million, up 4398.08% from the prior year.
• Restructuring Costs retreated to -$415000.0 in Q2 2026 per BVS's latest filing, from $454000.0 in the prior quarter.
• Across five years, Restructuring Costs topped out at $4.6 million in Q4 2022 and bottomed at -$415000.0 in Q2 2026.
• Historically, Restructuring Costs has averaged $691454.5 across 4 years, with a median of $454000.0 in 2026.
• The sharpest annual moves came in 2022 and 2023: Restructuring Costs soared 570.54% in 2022, then sank 104.52% in 2023.
• Over 4 years, Restructuring Costs stood at $4.6 million in 2022, then plunged by 101.54% to -$71000.0 in 2023, then climbed by 26.76% to -$52000.0 in 2024, then slumped by 698.08% to -$415000.0 in 2026.
• According to Business Quant data, Restructuring Costs over the past three periods registered -$415000.0, $454000.0, and -$52000.0 for Q2 2026, Q1 2026, and Q4 2024 respectively.